ClinicalTrials.gg
Active, not recruitingNCT06758102Updated Oct 26, 2026

Dance Study for Post-surgical Pain in Breast Cancer Survivors

An interventional study of Dance Program in Breast Cancer, Survivorship and Pain, Postoperative, sponsored by Dana-Farber Cancer Institute. Active, not recruiting at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Dana-Farber Cancer Institute · Not applicable, Interventional, and Supportive care

How we know

Updated Oct 26, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
28
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute — 15 open to participants now, 43 under way, none of them phase 3. Breast Neoplasms · Dana-Farber Cancer Institute.

Enrollment
99th of 132
28 · median 50
Started
2025
with 3 others
No phase
52 of 142
6 open now
Primary completion
2027-09
later than 27 of 42 live
Registered
135th of 142
by date

Among the 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute, this one is the 99th largest by enrollment of the 132 interventional ones that give a count, is one of 4 that started in 2025, is one of 52 with no phase, reaches primary completion later than 27 of the 42 other live ones, and was the 135th registered.

Breast Neoplasms

14,848 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

15 of the 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute are open now, in 2 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in Breast Neoplasms by Dana-Farber Cancer Institute, or all of them as a file.
02

Study summary

The purpose of this study is to examine how a 12-week, virtual dance program may improve pain and quality of life in participants with persistent post-surgical pain, or PPSP, following mastectomy or lumpectomy.

Read the detailed description

This is a single-arm, Phase 1 study is to assess how a 12-week, virtual dance program may improve persistent post-surgical pain (PPSP) and other participant-reported outcomes of quality of life, fatigue, and body image for breast cancer survivors following mastectomy or lumpectomy.

The study procedures including screening for eligibility and surveys.

Participation in this research study is expected to last up to 16 weeks.

It is expected that about 30 people will take part in this research study.

03

Conditions studied

  • Breast Cancer
  • Survivorship
  • Pain, Postoperative

Keywords

  • Breast Cancer Survivorship
  • Breast Cancer Survivor
  • Survivorship
  • Pain, Postoperative
  • PPSP
  • Persistent Post-Surgical Pain
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of Stage 0-III invasive breast cancer
  • Having undergone lumpectomy or mastectomy
  • Moderate to severe persistent post-surgical pain, as defined by pain scores ≥3 on a numerical rating scale (NRS) of 0-10 (10 being the most severe pain) at least 3 months after completion of surgery, chemotherapy, and/or radiation
  • Pain scores of 3-4 are categorized as moderate pain; scores of 5-10 are categorized as severe pain26
  • Age ≥ 18 years
  • Able to read and understand English (to complete required questionnaires and participate in classes)
  • Ability to provide
  • Ability to perform seated exercises

Exclusion criteria

Exclusion Criteria:

  • Unstable cardiovascular disease in the last 6 months
  • Psychiatric disorders or conditions that would preclude participation in the study intervention (e.g. untreated major depression or psychosis, untreated substance use disorder, severe personality disorder)
  • breast or other concurrent cancer
  • Pregnant
  • Recent history of attending regular dance or similar classes (e.g. yoga or tai chi classes i.e. 20 or more classes in the past 6 months)
  • Planned surgery anticipated during the intervention period
  • History of a chronic medical condition that has the potential to significantly impact upper extremity function (e.g. stroke, Parkinson's disease, Multiple Sclerosis)
  • Currently enrolled in a physical therapy course
  • Presence of medical conditions or medications that would prohibit participation in an exercise program
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    Dance Program

    30 enrolled participants will complete the following: * Baseline in-person or virtual visit with surveys. * 12 weekly virtual dance classes. * Follow up in-person or virtual visit with post-intervention surveys.

    Behavioral: Dance Program

Interventions

  • BehavioralDance Program

    A 12-week, virtual dance program consisting of seated and standing choreography and contemporary style elements will be taught by a certified dance instructor. Sessions will be conducted by the HIPAA-compliant, video-conferencing platform, Zoom.

06

What researchers measure

Primary outcomes

  1. Change in the Functional Assessment of Cancer Therapy Breast Symptom Index (FACT-B+4) Total Score from Baseline to 12 Weeks

    Assessed by the Functional Assessment of Cancer Therapy Breast Symptom Index (FACT-B+4), a 42-item measure of physical, emotional, social and functional well-being, as well as breast cancer specific symptomology associated with upper extremity dysfunction during the 7 days prior to questionnaire administration. Items are rated on a 5-point Likert-type scale with answers ranging from 0 "Not at all" to 4 "Very much." A total scores range is 0 to 168 with a higher score indicating better quality of life.

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Change in the Brief Pain Inventory Short Form (BPI SF) Score from Baseline to 12 Weeks

    Assessed by the Brief Pain Inventory Short Form (BPI SF), a 9-item measure of the severity of pain and pain interference in the 24 hour prior to questionnaire administrations. A simple numeric rating scale from 0 to 10 is used for item rating, and a total score is the mean of the item ratings. Higher scores indicate greater pain intensity and greater interference with function.

    Time frame: Baseline and 12 weeks

  2. Change in the Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-F) Total Score from Baseline to 12 Weeks

    Assessed by the Functional Assessment of Chronic Illness Therapy - Fatigue Scale (FACIT-F), a 13-item measure of the intensity of fatigue experienced during the 7 days prior to questionnaire administration. Items are rated on a 5-point Likert-type scale with answers ranging from 0 "Not at all" to 4 "very much" and items 7 and 8 being reversed score. A total scores range is 0 to 52 with a higher score indicating better quality of life.

    Time frame: Baseline and 12 weeks

  3. Change in the Cancer Rehabilitation Evaluation Scale (CARES) Score from Baseline to 12 Weeks

    Assessed by the Cancer Rehabilitation Evaluation Scale (CARES), a 6-item measure of body image and self-esteem by measuring negative feelings about the body and self-perception in the month prior to questionnaire administration. Items are rated on a 5-point Likert-type scale with answers ranging from 0 "Not at all" to 4 "Very much." A total scores range is 0 to 24 with a higher score indicating greater negative body image and self-esteem.

    Time frame: Baseline and 12 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Yes — The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data can be shared no earlier than 1 year following the date of publication

Access criteria: Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Sep 2027, 32 months after the start.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 32 months is close to that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Feb 2026 → Sep 2027 and completion Oct 2026 → Oct 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2024
First posted
Jan 3, 2025
StartActual
Jan 22, 2025
Primary completionEst.
Sep 28, 2027was Feb 2026
CompletionEst.
Oct 1, 2027was Oct 2026
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Feb 28, 2026→Sep 28, 2027
Oct 26, 2026
Study completion
Oct 1, 2026→Oct 1, 2027
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Primary completion Feb 28, 2026→Sep 28, 2027
    Study completion Oct 1, 2026→Oct 1, 2027

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06758102
Responsible party
Jennifer A. Ligibel, MD (Principal Investigator, Dana-Farber Cancer Institute) — Principal investigator
First posted
Jan 3, 2025
Start date
Jan 22, 2025
Primary completion
Sep 28, 2027 (estimated)
Completion
Oct 1, 2027 (estimated)
Last update
Oct 26, 2026

Study contacts

Jennifer Ligibel, MD
principal investigator · Dana-Farber Cancer Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion